Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV ®) vaccine up to 7 years following primary vaccination of children  & lt;  2 years of age with, or without, a booster vaccination

CONCLUSION: To extend protection, administering a booster of Typbar TCV® to children ∼5 years after their primary dose, i.e., coinciding with school entry, may be advisable. Typbar TCV® is presently the only WHO pre-qualified Vi conjugate vaccine with reported efficacy, effectiveness, and long-term immunogenicity findings.PMID:34625288 | DOI:10.1016/j.vaccine.2021.07.073

Source: Vaccine - October 9, 2021 Category: Allergy & Immunology Authors: Krishna Mohan Vadrevu Dugyala Raju Sandhya Rani Siddharth Reddy Vamshi Sarangi Raches Ella Bhuvaneswara Javvaji Niranjana S Mahantshetty Sudhakar Battu Myron M Levine Source Type: research